SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar KimLanners (< 20) Submitted: 3/17/2011 12:16:25 PM : Outperform Start Price: $3.50 SCLN Score: +61.63

low pe biotech

Featured Broker Partners


Advertisement